By FieldPulse Staff · March 19, 2026
Tags: launch, field, strategy
FDA clears semaglutide 7.2mg on March 19 with 20.7% average weight loss data. Novo plans April launch, adding a third SKU to an already crowded GLP-1 portfolio.
The FDA approved Wegovy HD (semaglutide 7.2 mg injection) on March 19, 2026, clearing a higher-dose version of Novo Nordisk's blockbuster weight-loss drug for adults with obesity or overweight with at least one weight-related condition. The new dose delivered a mean 20.7% body weight reduction in Phase 3 trials, with approximately 31% of participants losing 25% or more of their body weight — a benchmark that has become the gold standard in the obesity category. The approval notably came through the FDA Commissioner's new National Priority Voucher pilot program, enabling an accelerated review t